Response to pneumococcal vaccination in multiple myeloma
Loïc Renaud(Assistance Publique – Hôpitaux de Paris), Xavier Leleu(Inserm), Déborah Desmier, Thierry Façon(Université de Lille), Niels Moya(Inserm), Cécile Gruchet(Inserm), Guillemette Fouquet(Centre Hospitalier Universitaire de Lille), Salomon Manier(Université de Lille), Benjamin Carpentier, Charles Herbaux(Centre Hospitalier Universitaire de Lille), Stéphanie Guidez(Inserm), Thomas Systchenko(Inserm), Susanna Schraen(Centre Hospitalier Universitaire de Lille), Valentine Richez(Centre Hospitalier Universitaire de Nice), Arthur Bobin(Inserm), Antoine Machet(Inserm), Morgane Nudel(Centre Hospitalier Universitaire de Lille), Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), Émilie Cayssials(Centre Hospitalier Universitaire de Nice), Florence Sabirou(Inserm), Stephen Harding, Antony Levy(Inserm), Jean‐Luc Faucompré(Université de Lille), Claire Bories(Guy's and St Thomas' NHS Foundation Trust), Hélène Demarquette(Ikerbasque)
Cited by 24
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695